Eli Lilly wants to take big swings in Alzheimer’s, ALS, chronic pain and other difficult diseases after its success in ...

Eli Lilly’s (LLY) new weight loss pill is still in clinical trials and has not yet been approved by regulators. But that hasn ...

The weight-loss drug boom has transformed Eli Lilly (LLY), the maker of Zepbound, into the largest healthcare company in the ...

In this article, we will take a look into Eli Lilly and Co's (NYSE:LLY) DCF analysis, a reliable and data-driven approach to estimating its intrinsic value. Instead of using future free cash flow as ...

Weight-loss drugs such as Ozempic and Zepbound cost $900 to $1,500 for a month's supply.They cost so much partly because of ...

We recently published a list of Top 10 Stocks to Buy According to Sustainable Insight Capital Management. In this article, we ...

We recently compiled a list of the 10 Best Non-Tech Stocks to Buy Now for Long Term. In this article, we are going to take a ...

Citi analyst Geoff Meacham reiterated a Buy rating on Eli Lilly & Co (LLY – Research Report) today and set a price target of $1,190.00. The ...

Few big pharma stocks have been bigger winners over the last three years than Eli Lilly and Novo Nordisk. Lilly now ranks as ...

Eli Lilly was second to the lucrative GLP-1 market for diabetes and obesity following its chief metabolic medicine rival Novo ...

Senator Ron Wyden (D-Oregon) recently bought shares of Eli Lilly and Company (NYSE:LLY). In a filing disclosed on February 21st, the Senator disclosed that they had bought between $50,001 and $100,000 ...

Revenues in the biopharma industry continued to boom in the fourth quarter of last year, following a pattern seen ...